The aim of our study was to estimate whether molecular markers could detect significantly and help early diagnosis and improved survival of patients with CCR. In this work, we used some methods such as spectrometry, PCR, ELISA and PicoGreen® to evaluate the circulating DNA, the integrity of circulating DNA, the circulating RNA, the mRNA CA9 of serum and the circulating CA9 protein in the diagnosis or monitoring of CCR. The level of RNA and the mRNA CA9 of serum in patients with CRCC are higher than in healthy controls. In patients with CRCC, the level of circulating RNA is independent of age, gender, TNM stage, Fuhrman grade, and tumor size. The level of mRNA CA9 is independent of age, sexe et Fuhrman grade, but is correlated with TNM stage, presence of metastases and tumor size. According to our results, the circulating RNA and mRNA CA9 of serum can be used as diagnostic biomarkers of CRCC. By the spectrometry and the PicoGreen ® method, the average serum DNA in patients with CRCC was higher than in healthy controls, but this difference was not significant. Our results indicate that the sensitivity and specificity of serum DNA is not satisfactory for the diagnosis of CCR. In addition, the integrity of serum DNA in patients with CRCC was better than in patients with renal oncocytoma and also better than in healthy controls. The integrity of DNA in the serum could be a marker for the diagnosis of CRCC. The level of CA9 protein in patients with metastatic CRCC was higher than in patients with CRCC localized and also higher than in healthy controls. The high level of CA9 protein suggests a high risk of recurrence. The serum CA9 protein could be used to guide post-operative monitoring and may be indicating early adjuvant treatment of patients with high risk of recurrence in the future
